This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
Major Depressive Disorder
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
-
Neumora Investigator Site, Cerritos, California, United States, 90703
Neumora Investigator Site, Irvine, California, United States, 92614
Neumora Investigator Site, Long Beach, California, United States, 90807
Neumora Investigator Site, Brandon, Florida, United States, 33511
Neumora Investigator Site, Hialeah, Florida, United States, 33012
Neumora Investigator Site, Hialeah, Florida, United States, 33016
Neumora Investigator Site, Jacksonville, Florida, United States, 32256
Neumora Investigator Site, Maitland, Florida, United States, 32751
Neumora Investigator Site, Miami Beach, Florida, United States, 33140
Neumora Investigator site, Miami Springs, Florida, United States, 33166
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
No
Neumora Therapeutics, Inc.,
2025-06